三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
图24、罗替尼上市来销售情况
图24、罗替尼上市来销售情况
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:244KB
图片尺寸:1049*768
同报告图片
/
4
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
所属报告:
中国生物制药(1177.HK)-港股公司研究报告:加速创新与国际化制药龙头价值重估-250815(56页).pdf
打包全文图表
相关数据
中国I期伏罗尼布有效提升52周BCVA字母数
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
收藏
行业数据
2026-07-03
原图定位
查看详情
美国II期经治患者伏罗尼布减少了抗VEGF注射
fCDnu4TliKsgICAgICAgICAgIHwgNTLlkajlubPlnYfmipdWRUdG5rOo5bCE5qyh5pWwIHwg5qC35pys6YePbiB8CnwtLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS18CnwgWC04MiA1MG1nIFFEICAgIHwgNi43ICAgICAgICAgICAgICAgICAgfCA0MCAgICAgfAp8IFgtODIgMTAwbWcgUUQgICB8IDYuMCAgICAgICAgICAgICAgICAgIHwgMzkgICAgIHwKfCBYLTgyIDIwMG1nIFFEICAgfCA0LjcgICAgICAgICAgICAgICAgICB8IDM5ICAgICB8Cnwg5a6J5oWw5YmCICAgICAgICAgfCA4LjEgICAgICAgICAgICAgICAgICB8IDM5ICAgICB8CgrotYTmlpnmnaXmupDvvJpPcGh0aGFsbW9sb2d577yM5Zu95rOw5rW36YCa6K+B5Yi456CU56m2
收藏
行业数据
2026-07-03
原图定位
查看详情
图24.贝福替尼临床数据对比同类药物
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
收藏
行业数据
2026-01-13
原图定位
查看详情
匹米替尼未来在TGCT适应症的收入预测及对和誉的销售分成
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
收藏
行业数据
2025-10-10
原图定位
查看详情
针对和誉的CSF-1R抑制剂匹米替尼,在国际多地区和新适应症以及里程碑付款的预测
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
收藏
行业数据
2025-10-10
原图定位
查看详情
全球首个FGFR4抑制剂联合IO在HCC的临床设计:依帕戈替尼联合阿替利珠单抗的临床二期试验方案
PHxiZWdpbl9vZl9ib3h8PnwgUGFydCB8IERvc2UgUmVnaW1lbiAgICAgICB8IFNhbXBsZSBTaXplIChOKSB8CnwtLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS18CnwgQSAgICB8IDE4MG1nIFFEICAgICAgICAgICB8IDYgICAgICAgICAgICAgICB8CnwgQSAgICB8IDMyMG1nIFFEICAgICAgICAgICB8IDYgICAgICAgICAgICAgICB8CnwgQSAgICB8IDE2MG1nIEJJRCAgICAgICAgICB8IDggICAgICAgICAgICAgICB8CnwgQSAgICB8IDIyMG1nIEJJRCAgICAgICAgICB8IDMzICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7hQUFQ8fGVuZF9vZl9ib3h8Pg==
收藏
行业数据
2025-10-10
原图定位
查看详情
全球几款早于和誉依帕戈替尼进入临床阶段的FGFR4抑制剂,大部分都已经停止开发
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
收藏
行业数据
2025-10-10
原图定位
查看详情
匹米替尼在一期临床试验中对比另外两款CSR-1R抑制剂显示出最佳的安全性,且无任何肝脏相关不良反应
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
收藏
行业数据
2025-10-10
原图定位
查看详情
全球约30%的肝细胞癌患者存在异常的FGF19-FGFR4通路改变,依帕戈替尼(ABSK011)的独特设计MoA
fCDlnLDljLogICB8IOavj+W5tOaWsOWinueXheS+i+aVsCB8CnwtLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfAp8IOWFqOeQgyAgIHwg57qmMzDkuIcgICAgICAgICB8Cnwg5Lit5Zu9ICAgfCDnuqYxNeS4hyAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuFBQVO+8jOS+neW4leaIiOabv+WwvOmAmui/h+mdtuWQkUZHRjE5IC0gRkdGUjQg6YCa6Lev5rK755aX6IKd55mM
收藏
行业数据
2025-10-10
原图定位
查看详情
针对肝癌目前1L/2L治疗方案的ORR较低,mPFS较短,依帕戈替尼(ABSK011)有望改变这一状况
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
收藏
行业数据
2025-10-10
原图定位
查看详情
和誉首个商业化创新药匹米替尼(ABSK021)将
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
收藏
行业数据
2025-10-10
原图定位
查看详情
吡咯替尼或在国内乳腺癌新辅助治疗领域扮演帕妥珠单抗角色
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
收藏
行业数据
2025-09-28
原图定位
查看详情
吡咯替尼:HER2+乳腺癌全程用药布局
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
收藏
行业数据
2025-09-28
原图定位
查看详情
图表50艾玛昔替尼II/III期AS临床数据(应答率)
fCDmjIfmoIcgICAgICAgfCDlr7nnhafnu4TlupTnrZTnjocoJSkgfCDor5Xpqoznu4TlupTnrZTnjocoJSkgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS18CnwgQVNBUzIwICAgICB8IDI5LjAgICAgICAgICAgICAgfCA0OC43ICAgICAgICAgICAgIHwKfCBBU0FTNDAgICAgIHwgMTguMyAgICAgICAgICAgICB8IDMyLjEgICAgICAgICAgICAgfAp8IEFTQVM1LzYgICAgfCAxNS42ICAgICAgICAgICAgIHwgNDIuOCAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJpaLkxpIGV0IGFsLiBBIG11bHRpY2VudGVyLCByYW5kb21pemVkLCBkb3VibGUgLSBibGluZCw=
收藏
行业数据
2025-09-28
原图定位
查看详情
图表51艾玛昔替尼II/III期AS数据(较基线变化)
fCDmjIfmoIcgICAgICAgICAgfCBQbGFjZWJvIHwgU0hSMDMwMiA0IG1nIHwKfC0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS18LS0tLS0tLS0tLS0tLS18CnwgQkFTREFJICAgICAgICB8IC0xLjQzICAgfCAtMi4yMSAgICAgICAgfAp8IEJBU0ZJICAgICAgICAgfCAtMC43OSAgIHwgLTEuMzMgICAgICAgIHwKfCBCQVNNSSAobGluZWFyKXwgLTAuMjkgICB8IC0wLjQwICAgICAgICB8CnwgQVNRb0wgICAgICAgICB8IC0yLjE4ICAgfCAtMy4xMyAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77yaWi5MaSBldCBhbC4gQSBtdWx0aWNlbnRlciwgcmFuZG9taXplZCwgZG91YmxlLWJsaW5kLA==
收藏
行业数据
2025-09-28
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
C )3 线治疗 与 1/2 线软组织肉瘤治疗两适 症;2021 年医保续约纳入 1 线治疗甲状腺髓样 癌,2023 年续约纳入 1 线分化型甲状腺癌,2023 年医保续约后单 为 255 元/10mg,相较第一次进入医保降 39.8%。2024 年 5 月 6 日, 罗替尼第六个适症联合贝莫苏拜单抗、卡铂和依托泊苷治疗 1 线 ES-SCLC 获批上市,第七个 适 症既 系统性抗肿瘤失败且不适合进行根治性手术治疗或根治性放疗的非 MSI-H/dMMR 复发性或转移性子 内膜癌 2024 年 11 月 27 日获批上市。我 认为 罗替尼的医保续约降 一 程 上 响 其 2020 至 2024 年的销售增长,
行业数据
原图定位
当前图表所属:
中国生物制药(1177.HK)-港股公司研究报告:加速创新与国际化制药龙头价值重估-250815(56页).pdf
表9、罗替尼重点1线适症临数据
表4、LM-108临结果
表3、CCR8单抗在研进
表20、可比公司值
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》